US Patent

US7687052 — Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Method of Use · Assigned to University of Pennsylvania Penn · Expires 2027-04-30 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of imaging amyloid deposits and styrylpyridine compounds used in that imaging.

USPTO Abstract

This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4217`	—
`U-4217`	—
`U-4217`	—
`U-4217`	—

Patent Metadata

Patent number: US7687052
Jurisdiction: US
Classification: Method of Use
Expires: 2027-04-30
Drug substance claim: Yes
Drug product claim: Yes
Assignee: University of Pennsylvania Penn
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.